Member Info for DugWalker

Both sexes changed to both semester by auto spell checker....

One uses a limited sample size (typically a few hundred patients) and is a kind of screening trial to answer the question could this work? The latter has to demonstrate efficacy for a much much larger sample size (typically tens of thousands) with sufficient diversity to demonstrate efficacy for both semester, multiple ethnicities and all age ranges. It frequently involves randomised control trials and costs a lot of money.

OBD's tests are only laboratory 'validated'and this is why they are struggling to sell the 'flagship' CIRT test, the PSE and it is alsoʻ why the latest colerectal cancer test has a long road to travel before it can be successfully commercialised.

Ah OK Oilboy. Get where you are coming from now and can't argue with that! Utterly astonishing that this has not even got back to pre-placing price (~9p) yet.

Still the momentum will come and with so many positive news items to drop it could go ballistic at any time. Would much rather be in and waiting than try to time this and miss out as a result.

Also true Oilboy but I can't remember if we had even seen first gas at Selva back then. Now we have Selva, El Rom and Viura all in production and all with new wells in the pipeline. SP should already be well.into double figures.

Sells starting to appear as the penny drops for some that this is being pumped based only on wishful thinking.

Just amazing that so few have realised what is happening here. Flowrates increasing and gas prices rising, new permits closer by the day and reserves set to increase very substantially as Viura data lands.

This is a company that is printing money and has a second printer on order! Incredibly undervalued but for how long.

OBD has claimed to 'be in talks' with potential partners since their parlous financial situation and inability to monetise their tests became apparent. No JV investors or purchasers of OBD intellectual property have emerged because none of their tests are medically validated. A cohort of 350 patients is orders of magnitude lower than is required to satisfy medical regulators and fo the latest colerectol test simply joins their portfolio of unvalidated tests that they cannot sell.

Another placing is coming in a few months time.

As for Reddit. I'll go post their warning of desperate rampers seeking to profit from the misery of long term holders.

"Potential ability"

Also has "potential" to be fully validated but, if history teaches us anything, it won't be.

Day traders plaything now and with another placing looming in a few months time a dangerous share to try and time.

First to market is a huge commercial advantage and OBD is incapable of any sort of commercial focus. I doubt anyone at Guardian Health will be losing sleep at the prospect of OBD'S ineffective commercialisation team being further distracted from CIRT, PSA and the veterinary tests.

Shield Blood Test Approved for Colorectal Cancer Screening - NCI https://search.app/aLSbQauYhRsxhep1A

FDA approved and well ahead of OBD with respect to commet validation.

The problem with anpotential buyout is it has to account for the reality that a host of competitive liquid biopsy tests have emerged/are emerging. Maybe patent strategy is another aspect of commercialisation strategy that hasn't had sufficient attention?

Completely agree that the science is impressive and provides a basis for any number of powerful diagnostic tools. Unfortunately it appears that OBD continues to explot the science as an interesting academic tool via a scattergun approach to test development that de-prioritises the desperate need for proper medical validation as a precursor to commercialisation. My impression is that the science is determining ckorporate strategy rather than the commercial imperatives. The company continues to act as a black hole for shareholders money.

Confirmation of a positive direction of travel wrt Spanish permits. Also confirms that the development of multiple new wells will be phased which strongly suggests costs will be more than comfortably covered by the new revenue streams. Steady as she goes ....

Worth remembering that this is just a portion of the companies current income. The Viura acquisition more than doubled the combined production from Selva plus El Romeral and drilling of a new well at Viura will commence in a few months time. With TTF now at €52 there will be plenty of cash to finance PXEN's contribution to.the drilling costs.

This is the test mentioned by the BBC news today. Looks like OBD's dithering over validation has further shrunk their potential market.

Shield Blood Test Approved for Colorectal Cancer Screening - NCI https://search.app/vfZjq8stgdhh95KK6

Selva quarterly update, including revenues due end of this week. Should be swiftly followed by confirmation of flowrates at Viura wells following the recent workover of water disposal well. The combination of both should confirm upcoming drilling campaigns as self financed from existing revenue streams.

Strong and very positive newsflow over the coming few months will see the S.P. back in double figures.

Quarterly update from Italy due end next or beginning of following week will help confirm that revenues from 3 producing assets are exceeding €1 million per month. As an investment company operating is very small. Vast majority of revenues go straight onto bottom line.

Confirmation of flowrates from Viura wells is imminent and is likely to confirm increased production at a time of high TTF gas prices. Drilling of another Viura well to commence in a couple of months.

New permits expected in Italy and Spain H1 this year. Exploration licences in Poland also expected Q1/Q2 this year.

Major profitable growth seems assured and a significant re-rate should follow.

A fast track NHS deal is pie in the sky. Have you forgotten there's a national screening trial ongoing and that PSE isn't on the shortlist?

Increasingly convinced your posting for a laugh PI. Kinda admire your ironic sense of humour.

Increased competition from alternative technologies. No plan to have tests medically validated. Insufficient funds to finance trials at scale. No cost reduction measures. Global network of laboratories to service a handful of tests per day. Company chairman that fiddles whilst Rome burns. There are married reasons why the SP could drop significantly lower.

Hasn't raised enough to buy a small end of terrace run down town.

That level of retail interest suggests there will be no liquidity here. There is also no immediate prospect of them reaching break even let alone profitability. With the exception of Burrows it's the same overpaid underperforming management team. A share for those that refuse to learn from their mistakes.